University Health Network, Toronto, ON, Canada.
BMC Health Serv Res. 2012 Aug 28;12:281. doi: 10.1186/1472-6963-12-281.
Cardiovascular disease (CVD) is a leading cause of death in Canada and is a priority area for medical research. The research funding landscape in Canada has changed quite a bit over the last few decades, as have funding levels. Our objective was to estimate the magnitude of expenditures on CVD research for the public and charitable (not-for profit) sectors in Canada between 1975 and 2005.
To estimate research expenditures for the public and charitable sectors, we compiled a complete list of granting agencies in Canada, contacted each agency and the Canadian Institutes of Health Research (CIHR), and extracted data from the organizations' annual reports and the Reference Lists of health research in Canada. Two independent reviewers scanned all grant and fellowship/scholarship titles (and summary/key words, when available) of all research projects funded to determine their inclusion in our analysis; only grants and fellowships/scholarships that focused on heart and peripheral vascular diseases were selected.
Public/charitable sector funding increased 7.5 times, from close to $13 million (in constant dollars) in 1975 to almost $96 million (in constant dollars) in 2005 (base year). The Medical Research Council of Canada (MRCC)/CIHR and the Heart & Stroke Foundation of Canada have been the main founders of this type of research during our analysis period; the Alberta Heritage Foundation for Medical Research and the Fonds de la recherche en santé du Quebec have played major roles at the provincial level. The Indirect Costs Research Program and Canada Foundation for Innovation have played major roles in terms of funding in the last years of our analysis.
Public/charitable-funded research expenditures devoted to CVD have increased substantially over the last three decades. By international standards, the evidence suggests Canada spends less on health-related research than the UK and the US, at least in absolute terms. However, this may not be too problematic as Canada is likely to free-ride from research undertaken elsewhere. Understanding these past trends in research funding may provide decision makers with important information for planning future research efforts. Future work in this area should include the use of our coding methods to obtain estimates of funded research for other diseases in Canada.
心血管疾病(CVD)是加拿大的主要死亡原因,也是医学研究的重点领域。在过去的几十年中,加拿大的研究资金状况发生了很大变化,资金水平也发生了变化。我们的目标是估计 1975 年至 2005 年间加拿大公共和慈善(非营利)部门在 CVD 研究上的支出规模。
为了估计公共和慈善部门的研究支出,我们编制了加拿大拨款机构的完整清单,与每个机构和加拿大卫生研究院(CIHR)联系,并从组织的年度报告和加拿大卫生研究参考列表中提取数据。两名独立审查员扫描了所有资助机构和奖学金/奖学金的标题(以及可用的摘要/关键词),以确定它们是否包含在我们的分析中;仅选择了专注于心脏和外周血管疾病的赠款和奖学金/奖学金。
公共/慈善部门的资金增加了 7.5 倍,从 1975 年的近 1300 万美元(按不变价格计算)增加到 2005 年的近 9600 万美元(按不变价格计算)(基准年)。加拿大医学研究理事会(MRCC)/CIHR 和加拿大心脏与中风基金会是我们分析期间此类研究的主要发起者;艾伯塔省健康研究基金会和魁北克省健康研究基金会在省级层面发挥了重要作用。间接成本研究计划和加拿大创新基金会在我们分析的最后几年在资助方面发挥了重要作用。
过去三十年,用于 CVD 的公共/慈善资助研究支出大幅增加。按照国际标准,有证据表明,加拿大在健康相关研究方面的支出低于英国和美国,至少从绝对值来看是这样。然而,这可能不是一个太大的问题,因为加拿大可能会从其他地方进行的研究中获益。了解过去研究资金的这些趋势可能为决策者提供有关规划未来研究工作的重要信息。该领域的未来工作应包括使用我们的编码方法来估算加拿大其他疾病的资助研究。